Lhasa Limited shared knowledge shared progress

Publications

The following links provide access to relevant publications for the last 2 years. If you would like to view older publications, or to refine your search criteria further please search the library.

TitlePublishedTypeProducts
A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug ProductsMay 2022
An Evaluation of the Occupational Health Hazards of Peptide CouplersMay 2022Derek Nexus
Application of AOPs for Weight-of-Evidence Assessments: Rationalising Evidence for the ICH S1B(R1) Guidance AddendumApril 2022pdf file
Assessment of the dermal sensitisation potency of extractables and leachables using existing data and in silico methodsApril 2022pdf fileVitic NexusDerek Nexus
Collaborative analysis of complex nitrosaminesApril 2022pdf file
The Role of Expert Assessment and In Silico Predictions in Determining Genotoxic Risk of N-Nitrosamine ImpuritiesApril 2022pdf file
Updated Dermal Sensitisation Thresholds derived using an in silico expert system and an expanded Local Lymph Node Assay datasetApril 2022pdf fileDerek Nexus
Using Data Associated with a Developmental and Reproductive Toxicity Adverse Outcome Network to Aid Safety AssessmentsApril 2022pdf file
Using privacy-preserving federated learning to enable pre-competitive cross-industry knowledge sharing and improve QSAR modelsApril 2022pdf file
Interrogating AOP-Wiki knowledge as a networkApril 2022pdf file
How Well Do Defined Approaches Predict the Human Skin Sensitisation Potential of Previously Untested Chemicals?April 2022
Using adverse outcome pathways to contextualise (Q)SAR predictions for reproductive toxicity – A case study with aromatase inhibitionFebruary 2022
Nitrosamine Reactivity: A Survey of Reactions and Purge ProcessesNovember 2021Mirabilis
Developing structure-activity relationships for N-nitrosamine activityNovember 2021Derek Nexus
Supporting more scientifically driven risk assessments under ICH Q3DNovember 2021pdf file
Introduction to ICH Q3D guidance_The move from heavy metal testing to ICH Q3DNovember 2021pdf file
Supporting more scientifically driven risk assessments under ICH Q3D: Elemental Impurities Data Sharing_Webinar RecordingNovember 2021
ICH Q3D Drug Product Elemental Risk Assessment: The use of an elemental impurities excipients databaseOctober 2021
Structural features affecting nitrosamine carcinogenic potencySeptember 2021pdf file
In Silico Prediction of Genotoxicity Current Applications and Future PerspectivesSeptember 2021pdf fileDerek NexusSarah Nexus
Resolving conflicting data sources to a single call in Sarah Nexus [an infographic]September 2021pdf fileSarah Nexus
Zeneth Member Type InfographicAugust 2021pdf fileZeneth
2021 Webinar | Accessing vital sources of long-term carcinogenicity study data with Lhasa’s Carcinogenicity Database – An update and an overview - RecordingJuly 2021
2021 Webinar | Accessing vital sources of long-term carcinogenicity study data with Lhasa’s Carcinogenicity Database – An update and an overview - SlidesJuly 2021pdf file
QSAR 2021 Addressing the global challenge of N-nitrosamine impurity assessmentJune 2021pdf fileDerek NexusMirabilisSarah NexusVitic Nexus
QSAR 2021 - leveraging data from multiple sources to build QSARs through curation and federated learning in Effiris.June 2021pdf file
QSAR 2021 Is the bacterial reverse mutation assay an accurate predictor for N-nitrosamine carcinogenicityJune 2021pdf fileVitic Nexus
Predicting N-Nitrosamine Activity from SARJune 2021pdf fileDerek NexusSarah Nexus
Effiris_Improving in silico secondary pharmacology profiling using federated QSAR modelsJune 2021pdf file
Managing the risk of nitrosamine impuritiesJune 2021
Quantifying the nitrosamine potency distributionMay 2021pdf file
A collaborative benchmarking study to evaluate the newly released Zeneth 8May 2021pdf fileZeneth
In silico prediction of N-nitrosamine degradants in APIs that possess a secondary or tertiary amine functional groupMay 2021pdf fileZeneth
1. Qualifying impurities and degradation products: Anvisa's experience and technical improvement - Maria Rodrigues (Slides)May 2021pdf file
1. Qualifying impurities and degradation products: Anvisa's experience and technical improvement - Maria Rodrigues (Video)May 2021Zeneth
2. Risk assessment of potential mutagenic impurities in anti-hypertensive drug products approved in Brazil - Fernanda Waechter (Slides)May 2021pdf fileZeneth
2. Risk assessment of potential mutagenic impurities in anti-hypertensive drug products approved in Brazil - Fernanda Waechter (Video)May 2021Zeneth
3. Case studies on the qualification of impurities - Mariah Ultramari (Slides)May 2021pdf fileZeneth
3. Case studies on the qualification of impurities - Mariah Ultramari (Video)May 2021Zeneth
Data Sharing Projects using Vitic [an infographic]April 2021pdf fileExcipientsIntermediatesVitic Nexus
Development of an Adverse Outcome Pathway Network to Support an Integrated Approach to Testing and Assessment of Carcinogenic Risk - SOT 2021 Presentation SlidesMarch 2021pdf fileDerek Nexus
Systematic analysis of protein targets associated with adverse events of drugs from clinical trials and postmarketing reportsMarch 2021
The eTRANSAFE Project on Translational Safety Assessment through Integrative Knowledge Management: Achievements and PerspectivesMarch 2021
Case study on the use of integrated approaches to testing and assessment for the prediction of a 90-day repeated dose toxicity study (OECD 408) for 2-Ethylbutyric acid using a read-across approach from other branched carboxylic acids.March 2021
Guidelines for FAIR sharing of preclinical safety and off-target pharmacology dataMarch 2021
2021 Webinar - An overview of Effiris 2.1; An enhanced qualitative model suite for anticipating and mitigating adverse drug reactions – Slides and recordingFebruary 2021pdf file
Utilisation of parametric methods to improve percentile-based estimates for the carcinogenic potency of nitrosaminesFebruary 2021
Deriving compound-specific exposure limits for chemicals used in pharmaceutical synthesis: Challenges in expert decision-making exemplified through a case study-based workshopFebruary 2021
Beyond adverse outcome pathways: making toxicity predictions from event networks, SAR models, data and knowledgeJanuary 2021
Nexus ICH M7 Expert Review Support Functionality (an infographic)December 2020pdf fileDerek NexusSarah Nexus
Development of an Adverse Outcome Pathway Network to Support an Integrated Approach to Testing and Assessment of Carcinogenic RiskDecember 2020pdf file
HuskinDB, a database for skin permeation of xenobioticsDecember 2020
2020 AI/PDE Webinar -Acceptable Intake (AI) and Permitted Daily Exposure (PDE) data sharing project for pharmaceutical impurities - SlidesDecember 2020pdf file
2020 AI/PDE Webinar -Acceptable Intake (AI) and Permitted Daily Exposure (PDE) data sharing project for pharmaceutical impurities - RecordingDecember 2020
Application of adverse outcome pathways (AOPs) to support genotoxicity assessmentNovember 2020pdf file
2020 Zeneth 8 webinar - Zeneth 8: A re-designed and improved forced degradation prediction system for organic compounds - RecordingNovember 2020Zeneth
2020 Zeneth 8 webinar - Zeneth 8: A re-designed and improved forced degradation prediction system for organic compounds - SlidesNovember 2020pdf fileZeneth
Management of pharmaceutical ICH M7 (Q)SAR predictions – The impact of model updatesNovember 2020Derek NexusSarah NexusVitic Nexus
Anticipating and mitigating adverse drug reactions through machine learning and privacy-preserving data sharing (infographic)November 2020pdf file
Machine Learning Predicts Degree of Aromaticity from Structural FingerprintsNovember 2020
Session 4 - The growing network of genotoxicity AOPs - RecordingOctober 2020
Session 4 - The growing network of genotoxicityAOPs - SlidesOctober 2020pdf file
Session 4 - Combining knowledge and data on an AOP framework in order to take advantage of new and emerging methods In genotoxicity assessment - SlidesOctober 2020pdf file
Session 4 - Combining knowledge and data on an AOP framework in order to take advantage of new and emerging methods In genotoxicity assessment - RecordingOctober 2020
Session 3 - Exploiting AOPs as a framework to support ICH S1 risk assessments - SlidesOctober 2020pdf file
Session 3 - Exploiting AOPs as a framework to support ICH S1 risk assessments - RecordingOctober 2020
Session 3 - A pharmaceutical regulator’s view on the utility of adverse outcome pathways for carcinogenicity assessment - SlidesOctober 2020pdf file
Session 3 - A pharmaceutical regulator’s view on the utility of adverse outcome pathways for carcinogenicity assessment - RecordingOctober 2020
Session 2 - Integration of adverse outcome pathways with experimental data to support the assessment of carcinogenic risk - SlidesOctober 2020pdf file
Session 2 - Integration of adverse outcome pathways with experimental data to support the assessment of carcinogenic risk - RecordingOctober 2020
Session 2 - AOP and IATA complimentary frameworks to modernize chemical risk assessment - SlidesOctober 2020pdf file
Session 2 - AOP and IATA complimentary frameworks to modernize chemical risk assessment - RecordingOctober 2020
Could purge calculations support your regulatory submissions? (Infographic)October 2020pdf fileMirabilis
Session 1 - Creating a DART AOP network to enable improved decision-making during risk assessments - RecordingOctober 2020
Session 1 - Creating a DART AOP network to enable improved decision-making during risk assessments - SlidesOctober 2020pdf file
Session 1 - Building quantitative AOPs of the DARTable genome to explore risks of developmental toxicity - SlidesOctober 2020pdf file
Session 1 - Building quantitative AOPs of the DARTable genome to explore risks of developmental toxicity - RecordingOctober 2020
Developing Federated QSAR Models for Secondary PharmacologySeptember 2020pdf file
Integrating Knowledge Of Carcinogenicity Adverse Outcome Pathways (AOPs) With Experimental Data_EMGS Data Challenge 2020September 2020pdf fileDerek NexusVitic Nexus
Introducing the concept of virtual control groups into preclinical toxicology testingSeptember 2020ETOX
ICH M7 Expert Review Workshop: Resolving common prediction scenarios using automated arguments in Nexus 2.3 (Webinar Presentation Slides)September 2020pdf fileDerek NexusSarah Nexus
Setaria Product BrochureSeptember 2020pdf fileSetaria
Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity dataSeptember 2020Derek NexusSarah NexusVitic Nexus
Pathways for N-nitroso compound formation: secondary amines and beyondJuly 2020
Do all nitrosamines pose a significant level of genotoxic risk? (Webinar Presentation Slides)July 2020pdf fileDerek NexusSarah Nexus
Controlling a cohort - Understanding the risk of nitrosamines within drug substance synthesis (Webinar Presentation Slides)July 2020Mirabilis
ICH M7 Workshop Japanese ICGM 2019July 2020pdf fileSetariaSarah NexusMirabilisVitic NexusDerek Nexus
Use of Mirabilis based purge calculations to understand Nitrosamine-related risk and control strategy optionsJuly 2020Mirabilis
Evaluation of the Global Performance of Eight In Silico Skin Sensitization Models Using Human DataMay 2020Derek Nexus
Building Secondary Pharmacology Models: A Novel Approach to Proprietary Data Transfer.May 2020pdf file
Building Secondary Pharmacology Models: A Novel Approach to Proprietary Data Transfer - RecordingMay 2020
The Application of Adverse Outcome Pathways (AOPs) for Risk AssessmentMay 2020pdf file
Mirabilis Cost Saving InfographicApril 2020pdf fileMirabilis
Vitic Data Sharing BenefitsApril 2020pdf fileVitic Nexus
Who is using Vitic? InfographicApril 2020pdf fileVitic Nexus
Lhasa's Carcinogenicity Database - RecordingApril 2020
Introduction to the Lhasa Carcinogenicity Database - RecordingApril 2020
Accessing Carcinogenicity Potency DataApril 2020pdf file
Introduction to the Lhasa Carcinogenicity DatabaseApril 2020pdf file
Mirabilis Purge Ratio InfographicMarch 2020pdf fileMirabilis
Aiding and standardising expert review under ICH M7March 2020pdf file
In silico workflow under ICH M7March 2020pdf fileDerek NexusSetariaVitic NexusSarah Nexus
Aiding and standardising expert review under ICH M7 - RecordingMarch 2020
In silico workflow under ICH M7 - RecordingMarch 2020
Comparing and combining in silico outcomes and in vitro mechanism-based assays to predict genotoxicityMarch 2020pdf fileDerek NexusVitic Nexus
Updated Dermal Sensitisation Thresholds derived using an in silico expert system and an expanded Local Lymph Node Assay datasetMarch 2020pdf fileDerek NexusVitic Nexus
Utilising Adverse Outcome Pathways as a Framework to Organise Evidence and Support Carcinogenicity Risk AssessmentMarch 2020pdf file
Are All Nitrosamines Concerning?March 2020pdf fileVitic Nexus
Setaria - Managing Predictions, Data and Expert Review under ICH M7March 2020pdf fileSetaria
Predicting the safety of medicines in pregnancy: A workshop reportMarch 2020
ICH M7 Workshop - 2020 ICH M7 India RoadshowsMarch 2020pdf fileDerek NexusSarah NexusZenethVitic NexusSetariaMirabilis
Predictions, Data and ICH M7 - 2020 ICH M7 India RoadshowsMarch 2020pdf fileDerek NexusSarah NexusVitic NexusSetaria
Lhasa and the ICH M7 Guideline - 2020 ICH M7 India RoadshowMarch 2020pdf fileDerek NexusSarah NexusVitic NexusSetariaMirabilis
GSK MI risk assessment process Camicinal at al - 2020 ICH M7 India RoadshowMarch 2020pdf fileDerek NexusSarah NexusVitic Nexus
Hazard Assessment of Potentially Mutagenic Impurities - 2020 ICH M7 India RoadshowsMarch 2020pdf fileDerek NexusSarah Nexus
ICH M7 - Regulatory Updates and Industry Practices - 2020 ICH M7 India RoadshowsMarch 2020pdf fileDerek NexusSarah Nexus
Lhasa Expert Review Developments - 2020 ICH M7 India RoadshowsMarch 2020pdf fileDerek NexusSarah NexusVitic Nexus
Quantitative Analysis of In Vivo Dose-Response Data for Risk Assessment and Regulatory Decision Making - RecordingJanuary 2020
Approaches to Skin Sensitisation PredictionNovember 2019pdf fileDerek Nexus
Mirabilis - Case Study of a Risk Assessment for ICH M7 Control of ImpuritiesNovember 2019pdf fileMirabilis
2019 Webinar Zeneth 8: A faster, more intuitive, degradation predictive system - RecordingNovember 2019Zeneth
2019 Webinar Zeneth 8: A faster, more intuitive, degradation predictive system - SlidesNovember 2019pdf fileZeneth
Current advances in skin sensitization in silico predictions and their use in a defined approachOctober 2019pdf fileDerek Nexus
Development of the Mirabilis Knowledge Base for PMI Purge Prediction, Knowledge, Experience and Reaction MiningSeptember 2019pdf fileMirabilis
Improving the predictive performance of in silico aromatic amine mutagencitiy alertsSeptember 2019pdf file
ICH M7 - Risk assessment for mutagenic impurities and control strategiesSeptember 2019Derek NexusMirabilisSarah Nexus
2019 Pharmaceutical Industry and Regulators Symposium Recording - Day 2, Part 1August 2019
2019 Pharmaceutical Industry and Regulators Symposium Recording - Day 2, Part 2August 2019
2019 Pharmaceutical Industry and Regulators Symposium Recording - Day 2, Part 3August 2019
2019 Pharmaceutical Industry and Regulators Symposium Recording - Day 2, Part 4August 2019
2019 Pharmaceutical Industry and Regulators Symposium Recording - Day 1, Part 3August 2019
2019 Pharmaceutical Industry and Regulators Symposium Recording - Day 1, Part 4August 2019
2019 Pharmaceutical Industry and Regulators Symposium Recording - Day 1, Part 1August 2019
2019 Pharmaceutical Industry and Regulators Symposium Recording - Day 1, Part 2August 2019
Setting the basis for the mutagenicity assessment of new dyes: Application to the Max Weaver Dye LibraryAugust 2019pdf fileDerek Nexus
Setaria 3.0.1 Installation GuideAugust 2019pdf fileSetaria
Setaria 3.0.1 Release NotesAugust 2019pdf fileSetaria
Toxicity Evaluation of Degradation ProductsJuly 2019pdf fileDerek NexusSarah NexusZeneth
Valsartan – ImplicationsJuly 2019pdf file
(Q)SAR Evaluation of Drug Impurities from the US FDA Scientific PerspectiveJuly 2019pdf fileDerek NexusSarah Nexus
Managing Mutagenic Impurity Risks in Pharmaceutical ProductsJuly 2019pdf fileDerek NexusSarah Nexus
In silico prediction of MutagenicityJune 2019pdf fileSarah NexusDerek Nexus
Q3D Regulatory Case StudyJune 2019pdf fileVitic Nexus
ICHQ3D Implementation: Use of published data driven risk assessmentsJune 2019pdf fileVitic Nexus
RDC53: Challenges on impurities qualificationJune 2019pdf fileDerek NexusSarah NexusVitic NexusZeneth
Setaria 3.0 Installation GuideMay 2019pdf fileSetaria
A Suggested ICH M7 Framework Using Lhasa Limited ProductsMay 2019pdf fileZenethVitic NexusMirabilisSarah NexusDerek Nexus
Draft Reflection Paper - Non-Genotoxic ImpuritiesApril 2019pdf file
Improving In Silico Predictions in Developmental and Reproductive ToxicologyApril 2019Derek NexusSarah Nexus
How low can you go? An analysis of lowest effective dose in the Ames test.April 2019Vitic Nexus
A defined approach for predicting skin sensitisation hazard and potency based on the guided integration of in silico, in chemico and in vitro data using exclusion criteriaJanuary 2019Derek NexusVitic Nexus
Setaria 2.0 Installation GuideDecember 2018pdf fileSetaria
Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analysesDecember 2018
Save Time and Money with Lhasa LimitedDecember 2018pdf fileDerek NexusSarah NexusZeneth
Enhancing the ICH M7 Workflow through SetariaDecember 2018pdf fileSetaria
A Defined Approach for Predicting Skin Sensitisation Hazard and PotencyNovember 2018pdf fileDerek Nexus
Important considerations for the validation of QSAR models for in vitro mutagenicityNovember 2018Derek NexusSarah NexusVitic Nexus
Zeneth: an in silico tool to aid identification of degradantsOctober 2018pdf fileZeneth
Interpreting the Sensitivity and Equivocal Settings in Sarah NexusOctober 2018pdf fileSarah Nexus
Developing an adverse outcome pathway framework for carcinogenicity from alerts in an expert rule-based systemSeptember 2018pdf fileDerek Nexus
A Defined Approach to Skin Sensitisation: Integrating Derek Nexus with In Chemico/In Vitro Assays Based on Exclusion CriteriaAugust 2018pdf fileDerek Nexus
Vitic - A Faster, More Efficient Searching ExperienceJuly 2018Vitic Nexus
Elemental Impurities Data Sharing InitiativeJuly 2018pdf fileVitic Nexus
A pharma-wide approach to address the genotoxicity prediction of primary aromatic amines.June 2018
Perspectivas Regulatórias sobre a Qualificação de Produtos de Degradação e ImpurezasJune 2018pdf file
ICH M7 Overview: Predicting, Assessing, and Controlling Mutagenic Impurities from DegradationJune 2018pdf file
Use of In Silico for Assessing DegradantsJune 2018pdf fileZeneth
Supporting Lhasa Members in a Regulatory SettingJune 2018pdf file
Mirabilis: Using Mirabilis to Support Purge Arguments Under ICH M7June 2018pdf fileMirabilis
Mutagenicity Predictions using a Statistical SystemJune 2018pdf fileSarah Nexus
Toxicity Studies for Degradation Impurities - An Industry PerspectiveJune 2018pdf fileDerek NexusSarah Nexus
How Zeneth fits into ICH Q3DJune 2018pdf fileZeneth
Improving Toxicity Predictions through knowledge and data sharingJune 2018pdf fileDerek NexusExcipientsIntermediatesiPiEVitic Nexus
ICH M7 Use CasesJune 2018pdf fileDerek NexusSarah Nexus
An Elemental Impurities Excipient Database: A Viable Tool for ICH Q3D Drug Product Risk AssessmentMay 2018
A Defined Approach to Skin Sensitisation: Integrating Derek Nexus with In Chemico/In Vitro Assays - A SummaryApril 2018Derek NexusVitic Nexus
Derek Nexus and the Prediction of Human Skin Sensitisation Potential - A SummaryApril 2018Derek Nexus
Addressing the Challenge of Making Negative Predictions for Skin Sensitisation - A SummaryApril 2018Derek Nexus
Strain Profiles: Moving Beyond Binary Ames Classification - A SummaryApril 2018Sarah Nexus
Making reliable negative predictions of human skin sensitisation using an in silico fragmentation approachMarch 2018Derek NexusVitic Nexus
Sarah Nexus Strain InformationMarch 2018pdf fileSarah Nexus
Plans for Setaria - Incorporating Setaria into the Pfizer WorkflowMarch 2018pdf fileSetaria
Using New Features to Further Interrogate Sarah Nexus PredictionsMarch 2018pdf fileSarah Nexus
Strain profiles: Moving beyond binary Ames classificationMarch 2018pdf fileSarah Nexus
Addressing the Challenge of Making Negative Predictions for Skin SensitisationMarch 2018pdf fileDerek Nexus
Derek Nexus and the Prediction of Human Skin Sensitisation Potential: An EvaluationMarch 2018pdf fileDerek Nexus
A Defined Approach to Skin Sensitization Using Derek Nexus and Non-Animal AssaysMarch 2018pdf fileDerek Nexus
In Silico Prediction of DILI - Extraction of Histopathology Data from Preclinical Toxicity Data Studies of the eTOX Database for new In SIlico Models of HepatotoxicityMarch 2018pdf fileETOX
Skin sensitisation - What place does in silico have within a defined approach?March 2018pdf fileDerek Nexus
Setaria 1.2 Installation GuideFebruary 2018pdf fileDerek NexusSetaria
Potential impurities in drug substances: Compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromidesFebruary 2018
Nexus 2.2: An Overview of Key New Features - Sarah NexusJanuary 2018Sarah Nexus
Nexus 2.2: An Overview of Key New Features - Derek and Meteor NexusJanuary 2018Derek NexusMeteor Nexus
EC3: Methodology ExplainedJanuary 2018pdf fileDerek Nexus
Skin Sensitisation BrochureJanuary 2018pdf fileDerek NexusVitic Nexus
Observations on the Pharma's Industry Convergence toward CloudDecember 2017pdf file
Sarah Nexus: The Statistical System for ICH M7November 2017pdf fileSarah Nexus
An Overview of Lhasa Limited Collaborative Data Sharing InitiativesOctober 2017pdf fileDerek NexusETOXExcipientsIntermediatesVitic NexusiPiEMeteor NexusMIP DILIMirabilisSarah NexusSetariaZeneth
Negative Predictions for Skin Sensitisation 47th ICGMOctober 2017pdf fileDerek Nexus
Alternatives to in vivo testing for plant protection productsOctober 2017pdf fileDerek Nexus
Manual and Computational Methods for the Evaluation of Statistical Predictions Based on Expert AnalysisOctober 2017pdf fileDerek NexusSarah Nexus
In silico prediction of the skin sensitisation potential of non-quinonoid Michael acceptors: new reactivity assessments and evidence based precursor selectionSeptember 2017pdf fileDerek Nexus
Expert Review of In Silico Predictions for Skin Sensitization PotencySeptember 2017pdf fileDerek Nexus
Getting under the skin of an in silico approach to predicting dermal sensitisationAugust 2017pdf fileDerek Nexus
Integrated hazard identification of chemical sensitizers using in vitro and in silico readouts - A comparative evaluation of predictive performanceAugust 2017pdf fileDerek Nexus
Extrapolation of in vitro mutagenicity alerts to the in vivo endpoint in Derek NexusAugust 2017pdf fileDerek Nexus
A consortium-driven framework to guide the implementation of ICH M7 Option 4 control strategiesAugust 2017Mirabilis
Nothing to report? An in silico fragmentation methodology for making explicit negative predictions of skin sensitisationMay 2017pdf fileDerek Nexus
iPiE: Intelligence-led Assessment of Pharmaceuticals in the EnvironmentMay 2017pdf fileiPiE
Phosphite esters: a novel class of contact allergenApril 2017
Negative Predictions for Skin SensitisationApril 2017Derek Nexus
Expert Review of EC3 PredictionsApril 2017Derek Nexus
ICH M7 Classification WorkflowMarch 2017pdf fileDerek NexusSarah Nexus
A quantitative in silico model for predicting skin sensitization using a nearest neighbours approach within expert-derived structure–activity alert spacesMarch 2017Derek Nexus
Workbook: Expert Review of EC3 Predictions - a workshopMarch 2017pdf fileDerek Nexus
How important is expert review when measuring EC3 predictions in Derek Nexus?: Alkyl halides - a case studyMarch 2017pdf fileDerek Nexus
Performance of Derek Nexus’ In Silico EC3 Model for Predicting Dermal Sensitization PotencyMarch 2017pdf fileDerek Nexus
Utilization Of Derek Nexus Dermal Sensitization Predictions For Hazard Assessment At Bristol-Myers SquibbMarch 2017pdf fileDerek Nexus
In Silico Strategies to Assess Potentially Mutagenic Impurities Under ICH M7March 2017pdf fileDerek NexusSarah NexusMirabilisVitic Nexus
Using Sarah Nexus Effectively: Intuitive Model Building and Interpreting ConfidenceFebruary 2017Sarah Nexus
The Liability Load and how Lhasa Limited Focuses on Reducing itNovember 2016pdf fileDerek NexusSarah Nexus
Skin Sensitisation - Negative Predictions, Validations and Integrated Testing StrategiesOctober 2016pdf fileDerek Nexus
An Automated Classification Workflow to Assist Expert Assessment and Regulatory Submission for ICH M7August 2016pdf fileDerek NexusSarah Nexus
Practical Implementation of (Q)SAR and Expert Review for Compliance with ICH M7 GuidelinesApril 2016pdf file
Predicting the Purging of Impurities within an API Synthetic PathwayApril 2016pdf file
Evaluation Of The Statistics-Based Ames Mutagenicity Model Sarah Nexus And Interpretation Of The Results ObtainedApril 2016Sarah Nexus
Improvements to in silico predictivity after access to proprietary dataApril 2016Derek Nexus
Summation of Toxicity Data in ViticMarch 2016Vitic Nexus
Skin sensitisation: Now and the FutureMarch 2016pdf fileDerek Nexus
Mutagenic impurities: predicting alerting structures using in silico toolsMarch 2016pdf fileSarah NexusDerek Nexus
Predicting skin sensitisation using a decision tree integrated testing strategy with an in silico model and in chemico/in vitro assaysJanuary 2016Derek Nexus
It’s difficult, but important, to make negative predictionsJanuary 2016Derek Nexus
Undertaking Expert Review under ICH M7 - A Practical GuideDecember 2015pdf fileDerek NexusSarah Nexus
Investigation of an in vitro hepatotoxicity dataset to search for co-occurrence of signals amongst assays.December 2015pdf file
Evaluation Of A Statistics-based Ames Mutagenicity QSAR Model And Interpretation Of The Results ObtainedDecember 2015Sarah Nexus
Why data sharing is important - a case study using proprietary mutagenicity and skin sensitisation data.pdfNovember 2015pdf fileDerek Nexus
Practical examples of the new metabolism ranking system in Meteor Nexus.pdfNovember 2015pdf fileMeteor Nexus
Mutagenicity assessment strategy for pharmaceutical intermediates to aid limit setting for occupational exposureNovember 2015Sarah NexusDerek Nexus
Relationship between the mutagenicity of arylboronic acids and 11B NMR chemical shiftsMay 2015Derek Nexus
A practical application of two in silico systems for identification of potentially mutagenic impuritiesMay 2015Derek NexusSarah Nexus
An evaluation of in-house and off-the-shelf in silico models: Implications on guidance for mutagenicity assessmentApril 2015Derek Nexus
Nexus 2 - Improved functionality to assist in ICH M7 submissionDecember 2014Derek NexusSarah Nexus
How To - Filtering Mass DefectDecember 2014Meteor Nexus
In Silico Prediction of Pharmaceutical Degradation Pathways: A Benchmarking StudyOctober 2014Zeneth
Benchmarking Assessment of Salmonella Mutagenicity QSAR Models for Potential Use Under ICH M7.pdfMarch 2014pdf fileSarah Nexus
Addressing toxicity risk when designing and selecting compounds in early drug discoveryJanuary 2014Derek Nexus
Potentially mutagenic impurities: Analysis of structural classes and carcinogenic potencies of chemical intermediates in pharmaceutical syntheses supports alternative methods to the default TTC...August 2013Derek Nexus
An Expert System To Predict the Forced Degradation of Organic MoleculesJuly 2013Zeneth
Assessing Confidence in Predictions.wmvMay 2013Derek Nexus
Determination of compound-specific acceptable daily intakes for 11 mutagenic carcinogens used in pharmaceutical synthesisMarch 2013
Biotransformation Pathways of Biocides and Pharmaceuticals in Freshwater CrustaceansFebruary 2013Meteor Nexus
Food for thought - A toxicology ontology roadmapDecember 2012Derek Nexus
Assessing confidence in predictions made by knowledge-based systemsSeptember 2012Derek Nexus
In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: An industry surveyApril 2012
Expert Systems - The Use of Expert Systems in Drug Design-Toxicity and MetabolismJanuary 2012Derek NexusMeteor Nexus
Developing Structure-Activity Relationships for the Prediction of HepatotoxicityJune 2010Derek NexusMIP DILI
An in Silico Method for Predicting Ames Activities of Primary Aromatic AminesJanuary 2010Derek Nexus
A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicityApril 2006

© 2022 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Apart from the free survey software, we also have access to QuestionPro's free survey templates . We've found many of them useful and powerful to collect insights from various stakeholders of our organization.